Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

Publication date: June 2018Source: The Lancet HIV, Volume 5, Issue 6Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft, D:A:D study groupSummaryBackgroundAlthough earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV.MethodsThe prospective Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study consists of people living with HIV-1 from 11 cohorts in Australia, Europe, and the USA. Participants were monitored from Jan 1, 2009, until the earliest of a cardiovascular event, 6 months after the last visit, or until Feb 1, 2016. The outcome of interest was the incidence of cardiovascular disease in adults (aged ≥16 years) living with HIV who were being treated with contemporary treatments. We defined cardiovascular disease as centrally validated myocardial infarction, stroke, sudden cardiac death, or use of invasive cardiovascular procedures, including coronary bypass, coronary angioplasty, and carotid endarterectomy. We used Poisson regression ...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research